Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - Ampio Pharmaceuticals, Inc. | ampe-20200331ex312d109c4.htm |
EX-31.1 - EX-31.1 - Ampio Pharmaceuticals, Inc. | ampe-20200331ex311142247.htm |
10-Q - 10-Q - Ampio Pharmaceuticals, Inc. | ampe-20200331x10q.htm |
Exhibit 32.1
AMPIO PHARMACEUTICALS, INC.
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the filing of the quarterly report on Form 10-Q for the quarter ended March 31, 2020 (the “Report”) by Ampio Pharmaceuticals, Inc. (the “Company”), each of the undersigned hereby certifies to his knowledge that:
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and |
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: May 6, 2020 |
/s/ Michael Macaluso |
|
Michael Macaluso |
|
Chairman and Chief Executive Officer |
|
|
Dated: May 6, 2020 |
/s/ Daniel G. Stokely |
|
Daniel G. Stokely |
|
Chief Financial Officer, Treasurer and Secretary |